About i-sep
i-sep is a company based in Nantes (France) founded in 2015 by Sylvain Picot. i-sep has raised $3.61 million across 2 funding rounds from investors including GO CAPITAL. i-sep offers products and services including same™ system and IOCS Technology. i-sep operates in a competitive market with competitors including Haemonetics, VISIE, Sisu Global Health, Scinovia and Haermonics, among others.
- Headquarter Nantes, France
- Founders Sylvain Picot
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.61 M (USD)
in 2 rounds
-
Latest Funding Round
$2.73 M (USD), Series A
Sep 30, 2019
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of i-sep
i-sep offers a comprehensive portfolio of products and services, including same™ system and IOCS Technology.
Technology for recovering red blood cells and platelets in surgeries.
System that enables intraoperative cell salvage for patient safety.
People of i-sep
Unlock access to complete
Unlock access to complete
Funding Insights of i-sep
i-sep has successfully raised a total of $3.61M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.73 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in i-sep
i-sep has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include GO CAPITAL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked |
Investor details for i-sep
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by i-sep
Investment portfolio details for i-sep
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - i-sep
Detailed financials for i-sep
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
I-Sep Comparisons
Peer comparison for i-sep
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of i-sep
i-sep operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Haemonetics, VISIE, Sisu Global Health, Scinovia and Haermonics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Hematology products and solutions are provided for medical applications.
|
|
| Locked | Locked | Locked |
Provider of 3D intraoperative imaging technology for orthopedic, neuro, and spine surgery
|
|
| Locked | Locked | Locked |
Intraoperative autotransfusion devices are developed and provided.
|
|
| Locked | Locked | Locked |
Augmented-reality surgical cameras for blood flow visualization are developed.
|
|
| Locked | Locked | Locked |
Postoperative pericardial drainage and flushing system is developed.
|
|
| Locked | Locked | Locked |
Develops medical devices for intraoperative blood recovery and conservation.
|
Detailed competitors of i-sep
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on I-Sep
Complete news archive for i-sep
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about i-sep
i-sep was founded in 2015.
i-sep is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
Sylvain Picot is the current CEO of i-sep. They have also founded this company.
i-sep is a funded company, having raised a total of $3.61M across 2 funding rounds to date.
i-Sep develops advanced cell salvage solutions. Intraoperative blood salvage, also known as autologous blood transfusion or cell salvage, is a medical procedure involving recovering blood lost during surgery and re-infusing it into the patient. It is a form of autotransfusion. These are used frequently in cardiothoracic and vascular surgery, in which blood usage has traditionally been high. With a greater effort to avoid adverse events due totransfusion there has also been an emphasis on blood conservation.
i-sep's top competitors include Haemonetics, VISIE and Sisu Global Health.
i-sep offers same™ system and IOCS Technology.
i-sep has 1 investor. Key investors include GO CAPITAL.